COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cancer patients face varying COVID-19 risks based on tumor type. Hematological malignancies and older age increase mortality risk, while chemotherapy further elevates death rates during hospitalization. Personalized risk assessment is crucial for patient care.
Area Of Science
- Oncology
- Infectious Diseases
- Epidemiology
Background
- Cancer patients are considered at higher risk for adverse COVID-19 outcomes.
- Cancer is a complex disease with diverse subtypes, necessitating subtype-specific risk assessment.
- Understanding COVID-19 risk variations within cancer populations is critical for patient management.
Purpose Of The Study
- To investigate COVID-19 risk stratification in cancer patients based on tumor subtype and demographics.
- To analyze the prevalence and case-fatality rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in relation to cancer type.
- To provide data for informed clinical decision-making and public health policies regarding cancer patients and COVID-19.
Main Methods
- Comparison of adult cancer patients from the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort with a non-COVID-19 UK cancer control population.
- Analysis of primary tumor subtype, age, and sex as factors influencing SARS-CoV-2 prevalence and COVID-19 case-fatality rates.
- Utilized univariable and multivariable models to assess the impact of tumor subtype and patient demographics on COVID-19 outcomes.
Main Results
- The overall case-fatality rate for COVID-19 in cancer patients increased significantly with age.
- Patients with hematological malignancies exhibited a more severe COVID-19 trajectory compared to those with solid tumors (OR 1.57).
- Leukemia patients had a higher case-fatality rate (2.25), and recent chemotherapy in hematological malignancy patients increased death risk during hospitalization (OR 2.09).
Conclusions
- COVID-19 susceptibility and outcomes vary significantly among different cancer subtypes.
- Individualized risk tables incorporating age, sex, and tumor subtype can aid physicians in risk-benefit discussions.
- Evidence-based risk stratification supports tailored social isolation policies for cancer patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...